Found: 6
Select item for more details and to access through your institution.
An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.856386
- By:
- Publication type:
- Article
An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.856386
- By:
- Publication type:
- Article
Canagliflozin Ameliorates Ventricular Remodeling through Apelin/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats.
- Published in:
- Pharmacology, 2023, v. 108, n. 5, p. 478, doi. 10.1159/000533277
- By:
- Publication type:
- Article
MiR-21 attenuates FAS-mediated cardiomyocyte apoptosis by regulating HIPK3 expression.
- Published in:
- Bioscience Reports, 2023, v. 43, n. 9, p. 1, doi. 10.1042/BSR20230014
- By:
- Publication type:
- Article
Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats.
- Published in:
- Journal of International Medical Research, 2023, v. 51, n. 10, p. 1, doi. 10.1177/03000605231206289
- By:
- Publication type:
- Article
Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice.
- Published in:
- Drug Design, Development & Therapy, 2022, v. 16, p. 4161, doi. 10.2147/DDDT.S388823
- By:
- Publication type:
- Article